Takeda, new cancer biotech and more—FiercePharmaAsia by Angus Liu Friday, February 8, 2019 Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.
Takeda pulls Ninlaro myeloma maintenance filing by Angus Liu Friday, February 1, 2019 Takeda withdrew an FDA filing for Ninlaro in post-transplant maintenance because it doesn't yet have survival data the agency wants.
Takeda-Shire votes, J&J-Legend and more—FiercePharmaAsia by Angus Liu Friday, December 7, 2018 The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Takeda maintenance data set up Ninlaro for new nod by Carly Helfand Sunday, December 2, 2018 Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.
Big Pharmas slash cancer drug prices again for Chinese insurance by Angus Liu Wednesday, October 10, 2018 Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Takeda CEO sees China as firm's possible second-largest business by Angus Liu Wednesday, July 18, 2018 Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.
Takeda executives expect Velcade sales to plummet 30% by Angus Liu Monday, May 14, 2018 Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.
FiercePharmaAsia—Eli Lilly, OrbiMed, Takeda by Angus Liu Friday, September 8, 2017 Lilly will close its Shanghai R&D center, OrbiMed sets up its third Asia healthcare fund, and Takeda marches into CAR-T with a new deal.
NICE burns Takeda again with second Ninlaro rejection by Carly Helfand Wednesday, September 6, 2017 Takeda's CEO has said Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But NICE could get in the way.
